<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Glioblastomas are the most common and most lethal forms of malignant primary brain tumor. We present a case report of a patient with III-grade glioma who achieved stable disease (SD) and clinical improvement after trametinib administration. We also report a review of the literature to Current Treatment Guidelines of Glioblastoma and new therapeutic strategies based on molecularly targeted therapy. Traditional treatments, including surgery, radiotherapy, and chemotherapy, have many limitations concerning the prognosis of patients with glioblastomas. Unfortunately, these tumors’recur after primary resection in the majority of cases. There is no standard therapy for recurrence of GBM. Targeted therapy offers a promising new treatment strategy. Regardless of those outstanding results much more can be done in the field of therapeutic options. Most urgent concerns include potent combining molecular targeted therapy with other types of treatments, selecting a group of patients for whom they turn out to be the most beneficial, and addressing adverse events of these molecules.</p>
</abstract>

Glioblastomas are the most common and most lethal forms of malignant primary brain tumor. We present a case report of a patient with III-grade glioma who achieved stable disease (SD) and clinical improvement after trametinib administration. We also report a review of the literature to Current Treatment Guidelines of Glioblastoma and new therapeutic strategies based on molecularly targeted therapy. Traditional treatments, including surgery, radiotherapy, and chemotherapy, have many limitations concerning the prognosis of patients with glioblastomas. Unfortunately, these tumors’recur after primary resection in the majority of cases. There is no standard therapy for recurrence of GBM. Targeted therapy offers a promising new treatment strategy. Regardless of those outstanding results much more can be done in the field of therapeutic options. Most urgent concerns include potent combining molecular targeted therapy with other types of treatments, selecting a group of patients for whom they turn out to be the most beneficial, and addressing adverse events of these molecules.

New therapeutic strategies based on molecularly targeted therapy in glioblastoma – a case report and review of the literature

Department of Clinical Oncology and Chemotherapy

Current Issues in Pharmacy and Medical Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Glioblastomas are the most common and most lethal forms of malignant primary brain tumor. We present a case report of a patient with III-grade glioma who...

New therapeutic strategies based on molecularly targeted therapy in glioblastoma – a case report and review of the literature

Publié en ligne: 09 févr. 2023

Pages: 206 - 211

Reçu: 07 sept. 2022

Accepté: 01 déc. 2022

DOI: https://doi.org/10.2478/cipms-2022-0036

Mots clés
glioblastoma multiforme (GBM), treatment, case report, review of the literature

© 2022 Katarzyna Szklener et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

New therapeutic strategies based on molecularly targeted therapy in glioblastoma – a case report and review of the literature

Publié en ligne: 09 févr. 2023

Pages: 206 - 211

Reçu: 07 sept. 2022

Accepté: 01 déc. 2022

DOI: https://doi.org/10.2478/cipms-2022-0036

Mots clésglioblastoma multiforme (GBM), treatment, case report, review of the literature

© 2022 Katarzyna Szklener et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
glioblastoma multiforme (GBM), treatment, case report, review of the literature